PODD · Insulet Corporation
Price
Snapshot
50 fields · last close| Market Cap | $11.44B |
| P/E | 28.61 |
| Float | 69.11M |
| Beta | 1.08 |
| Volatility 30D | 32.4% |
| Exchange | NASDAQ |
| Sector | Health Care |
| Cap tier | Large cap |
| Macro sensitivity | Moderate |
| Clavix score | 70.4 |
| Price | 153.34 |
| Change | −7.08% |
| Prev Close | 165.02 |
| Open | 148.61 |
| Day Low | 148.55 |
| Day High | 165.46 |
| Avg Vol | 1 |
| Avg $ Vol | $203.8M |
| 52W High | 354.88 |
| 52W Low | 126.40 |
| 52W Pos | 11.8% |
| From High | −56.79% |
| From Low | +21.31% |
| Max DD 1Y | −62.33% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | +5.43% |
| SMA 50 | +8.25% |
| SMA 200 | −13.31% |
| RSI (14) | 77.2 |
| Vol 90D | 51.4% |
| Vol 1Y | 47.0% |
| 1Y Range | 126–355 |
| Daily bars | 549 |
| Perf Week | +10.80% |
| Perf Month | +22.48% |
| Perf Quarter | +18.46% |
| Perf Half Y | +9.08% |
| Perf Year | −48.23% |
| Perf YTD | −45.80% |
| Prev Day | −7.08% |
| Clavix | B- |
| Debt / Eq | 0.93 |
| Curr Ratio | 2.81 |
| Int Cover | 14.7× |
| FCF Margin | 14.0% |
| Rev Growth | +30.7% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 41 / 49 |
What PODD does
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.
It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy.
The company sells its products to end-users through the pharmacy channel; and independent distributors.
Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Clavix risk grade
regraded every trading dayPODD grades B-, 70.4 of 100. Steadiest on News Sentiment (67), most exposed on Price Stability (50, mixed). 1 of the 4 weighted dimensions sit above the Health Care median. Ranks 41 of 49 in Health Care by Clavix score.
How rough the ride is
| PODD | Health Care median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.08 | 0.79 |
| 30-day realized volatilityannualized, from daily closes | 32.4% | 36.1% |
| Max drawdown, past yearworst peak-to-trough fall | −62.3% | — |
| Typical daily movemedian absolute daily change | 1.38% | — |
| Days beyond ±3%of the last 252 sessions | 49 (19%) | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| PODD | Health Care median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.08 | 0.79 |
| Macro sensitivityrate, dollar and credit exposure bucket | Moderate | Moderate 51% of 49 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Health Care names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| PODD | |
|---|---|
| 1 week | +10.8% |
| 1 month | +22.5% |
| Year to date | −45.8% |
| 1 year | −48.2% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| PODD | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30 since 31 Aug |
| Average score0 most bearish, 100 most bullish | 49 |
| Bullish · bearisharticles above 60 · below 40 | 10 · 12 |
| Directionarticles whose tone is improving vs worsening | 10 ↑ 12 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 49 Health Care names Clavix covers; the tick is the sector median.
Growth
| PODD | |
|---|---|
| Revenue growthyear over year | +30.7% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Health Care median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Recent news
most recent scored articles · the chip is the article’s score · click to openInsulet reported third-quarter revenue of $842 million, up 19.2%, or 19.6% when the effect of currency changes is removed. International growth exceeded the company's plans, while U.S. results stayed within its forecast range.
Insulet reported third-quarter earnings of $1.99 per share, above the $1.59 analysts' consensus estimate and $1.24 a year earlier. The headline also says revenue exceeded estimates, but the article provides no revenue figure or explanation for the results.
Insulet is due to report earnings next week, with Wall Street expecting earnings growth. The article says Insulet lacks the combination of two factors needed for a likely earnings beat, but it does not identify those factors or provide financial estimates.
Wall Street Zen lowered its rating of Insulet (PODD) from "buy" to "hold" in a Saturday report. The article provides no price target, reasoning, or company-specific information.
The Federal Circuit denied Insulet's request to keep a court order against EOFlow in place while Insulet appeals the overturning of a $59 million trade-secret jury verdict to the U.S. Supreme Court.
Nearest peers by size
Health Care| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| GMED | Globus Medical, Inc. | B+ | $11.69B | 19.96 | 0.93 | Compare |
| ALGN | Align Technology, Inc. | B | $11.71B | 27.75 | 1.72 | Compare |
| MOH | Molina Healthcare Inc | B | $11.82B | 22.99 | 0.69 | Compare |
| DVA | DaVita Inc | B | $12.12B | 12.75 | 0.82 | Compare |
| COO | The Cooper Companies, Inc. | B | $12.25B | 20.28 | 0.79 | Compare |
| UHS | Universal Health Services, Inc. | A- | $10.47B | 7.56 | 1.10 | Compare |
| PEN | Penumbra, Inc. | A+ | $12.71B | 79.35 | 0.65 | Compare |
| HSIC | Henry Schein, Inc. | A- | $9.83B | 24.29 | 0.85 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. 1 month free on iPhone.